Emtricitabine, Rilpivirine and Tenofovir Disoproxil vs Emtricitabine — Cost, Coverage & Plan Comparison

Pick the drugs you want to compare.

Up to 4 drugsCross-class or same-class

Start with the molecules your plan spends the most on. Most useful comparisons live within the same therapeutic class — switching across classes requires deeper clinical review.

Drug 1

Drug 2

Drug 3 (optional)

Drug 4 (optional)

Side by side, line by line.

Federal data onlyNo PBM pricing assumed

Compare across

11 dimensions

Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor

Emtricitabine, Rilpivirine and Tenofovir Disoproxil

First FDA approval: 2026-03-05

Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor

Emtricitabine

Brand: Emtriva

First FDA approval: 2003-07-02

Lowest NADACAcquisition cost floor across all NDCs

—Per unit

$14.51Per unit

Average NADACAcross all dosage forms and strengths

—

$15.49Up to $17.44

Generic manufacturersActive ANDA holders — FDA Orange Book

00 total ANDAs filed

22 total ANDAs filed

Annualized Part D spendCY2024 — CMS Part D Spending Dashboard

—Full year

$3.0MFull year

Part D claims (CY24)Total fills, all strengths

—— beneficiaries

8K2K beneficiaries

Avg cost per claimCalculated: total spend ÷ total claims

—Per claim, all NDCs

$386Per claim, all NDCs

Part D plans surveyed2026 plan year — CMS Formulary file

329Across CMS plan year

Prior-authorization frictionPlan-NDC pairs requiring PA

—Zero PA friction

0Zero PA friction

Step therapy appliedPlan-NDC pairs requiring step therapy

—None

0None

FDA shortage statusLive cross-reference vs FDA Drug Shortage Database

NoneClear

Generic availableFDA Orange Book

NoBrand-only

Yes2 manufacturers